Happy holidays from all of us at P4ADNow!
Welcome to the Week in Review.
1. Patients Take Stories To The White House
- Three patient advocates living with type 1 diabetes shared their stories directly with President Biden and Vice President Harris this week. IeshaMeza, from Phoenix, shared her experiences with high insulin prices and introduced the president ahead of his speech on the drug pricing reforms in the reconciliation package. Sa’Ra Skipper, from Indianapolis, also met with President Biden, who went on to mention her story in his speech. The White House also released a video of Gail deVore, a patient advocate from Denver who previously met with the president, speaking with the vice president about the need for Congress to pass the Build Back Better Act to lower drug prices for patients. We are so thankful for all patients speaking out and working tirelessly to pass Build Back Better. — (P4ADNow)
2. This Is Why We Need Drug Pricing Reforms
- On Friday, P4AD founder David Mitchell spoke at a press conferencealongside congressional leaders and advocates, including Speaker Pelosi and House Oversight Committee Chairwoman Maloney, revealing the final findings of the committee’s three-year investigation into pharmaceutical pricing practices. The report draws into sharp focus the need for the drug pricing reforms in the Build Back Better Act. “When this bill is signed into law, it will mark a truly historic shift in U.S. policy and deliver long overdue relief to millions of Americans,” Mitchell said. “We are calling on the Senate to pass the legislation, resist efforts by Big Pharma that are still going on to weaken this bill in any way. Millions of American lives depend on it.” — (P4ADNow)
3. Loud And Clear
- In a new poll from Morning Consult and Politico, voters from both sides of the aisle say that Medicare negotiation is one of the most important provisions in the Build Back Better Act, with over 40 percent of people naming it as one of their top five issues. Yet again, the polling is clear: Medicare negotiation for lower drug prices is a bipartisan priority for American voters. Now, it’s up to the Senate to deliver on Americans’ wishes. — (Morning Consult)